Y-mAbs Therapeutics, Inc.
NASDAQ: YMAB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Rossi
- Employees
- 104
- Headquarters
- Princeton, United States
- IPO year
- 2018
- Market cap
- $391.2M
- Website
- https://www.ymabs.com
Loading YMAB…
Loading profile data…Frequently asked questions about YMAB
What does Y-mAbs Therapeutics, Inc. (YMAB) do?
Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship product, DANYELZA, is a monoclonal antibody administered alongside granulocyte-macrophage colony-sti...
Where does YMAB trade?
Y-mAbs Therapeutics, Inc. (YMAB) trades on the NASDAQ Global Select.
What sector is YMAB in?
Y-mAbs Therapeutics, Inc. (YMAB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Y-mAbs Therapeutics, Inc.?
Michael Rossi is the chief executive officer of Y-mAbs Therapeutics, Inc. (YMAB).
Where is Y-mAbs Therapeutics, Inc. headquartered?
Y-mAbs Therapeutics, Inc. is headquartered in United States.
Does YMAB pay a dividend?
Y-mAbs Therapeutics, Inc. (YMAB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did YMAB go public?
Y-mAbs Therapeutics, Inc. (YMAB) completed its initial public offering in 2018.